Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTOPICALGeneric

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

Standard Dose
EQ 0.05% BASE;1%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE is listed in Drugs@FDA under application 202894 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE Form and strength CREAM;TOPICAL - EQ 0.05% BASE;1% Sponsor GLENMARK SPECLT Submission history Latest submission status date: 2020-05-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE is listed in Drugs@FDA under application 202894 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE Form and strength CREAM;TOPICAL - EQ 0.05% BASE;1% Sponsor GLENMARK SPECLT Submission history Latest submission status date: 2020-05-29 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE (BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE) | Drug Monograph | MedicHelpline